Intercept Pharmaceuticals (ICPT) Outlook Unchanged Following Earnings - Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Intercept Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Business Update
November 9, 2015 7:05 AM ESTNEW YORK, Nov. 9, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases, today reported financial results for the three and nine months ended September 30, 2015 and provided other general business updates. Intercept will hold a conference call and audio webcast today at 8:00 a.m. ET to review this information with conference call details provided below.
Summary of Key Development Programs, Updates and Anticipated Milestones
Nonalcoholic Steatohepatitis (NASH) Program-- REGENERATE... More
